ClinicalTrials.gg
RecruitingNCT07379710Updated Oct 21, 2026

Norepinephrine With Ephedrine Versus Norepinephrine Alone During Spinal Anesthesia for Cesarean Delivery

A Phase 4 interventional study of Ephedrine and Norepinephrine infusion and Norepinephrine infusion in Incidence of Post-spinal Hypotension, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Cairo University · Phase 4, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 21, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing ephedrine in Hypotension — 4 open to participants now, 4 under way, none of them phase 3. Ephedrine · Hypotension.

Planned enrollment
Largest of 22
260 · median 120
Started
2026
with 1 other
Phase 4
11 of 22
2 open now
Registered
21st of 22
by date
Lead sponsor
2 of 22
Cairo University

Among the 22 studies testing ephedrine in Hypotension, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 11 in phase 4, and was the 21st registered.

Hypotension

892 studies on the registry are indexed under Hypotension; 199 are open to participants now.

Browse Hypotension studies →

Open to participants now

4 of the 22 studies testing ephedrine in Hypotension are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ephedrine

Ephedrine: first FDA approval 2016 (AKOVAZ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ephedrine in Hypotension, or all of them as a file.
02

Study summary

We hypothesize that the addition of ephedrine to norepinephrine infusion could decrease the incidence of post spinal hypotension(PSH) in parturient undergoing C.S under spinal anesthesia and minimize the changes in heart rate

Read the detailed description

Aim of the work: To compare between concomitant use of norepinephrine infusion with ephedrine versus use of norepinephrine infusion alone on maternal B.P following induction of spinal anaesthesia for C.S delivery.

Statistical analysis Sample Size: Our primary outcome is the incidence of post-spinal hypotension. In a previous study incidence of post spinal hypotension in the noradrenaline group was 32%. We calculated a sample size that could detect at least 50% difference between study groups. Using MedCalc Software version 14 (MedCalc Software bvba, Ostend, Belgium), a sample size of 246 patients will be needed to have a study power of 80% and alpha error of 0.05. The number was increased to be 260 envelopes (130 envelopes per group) to compensate for possible dropouts.

Statistical analysis:

Analysis of data will be performed using Statistical package for social science (SPSS) software, version 26 for Microsoft Windows (SPSS Inc., Chicago, iL, USA). Categorical data will be reported as frequency and percentages and will be analyzed using chi-squared test. Continuous data will be checked for normality using Kolmogorov-Smirnov test. Normally distributed data will be presented as means ±standard deviations and will be analyzed using unpaired student t-test.

Skewed data will be expressed as medians(quartiles) and will be analyzed using Mann Whitney U test. A two-way repeated measures ANOVA will be used to evaluate dose (between-groups factor) and time (repeated measures)". P value of 0.05 or less will be considered significant.

03

Conditions studied

  • Incidence of Post-spinal Hypotension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • II
  • Age: 18 to 40 years
  • Undergoing Elective Lower Segment Cesarean Section under Spinal Anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled cardiac morbidities As reduction of \< 60%, History (within 3months) of myocardial infarction, cerebrovascular accident, or coronary artery disease/stents
  • Poorly controlled Hypertensive disorders of pregnancy
  • Peripartum bleeding
  • Coagulation disorders
  • Baseline systolic blood pressure (SBP) \< 100 mmHg
  • Refusal of patients.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Active comparator
    Group(A)

    Ephedrine 10 mg (2.5mg/ml) direct I.V will be given simultaneous with Norepinephrine infusion 0.08 mcg/kg/min

    Drug: Ephedrine and Norepinephrine infusion

  • Active comparator
    Group (B)

    4 ml normal saline direct I.V will be given simultaneous with norepinephrine (to keep blinding) Infusion 0.08 mcg/kg/min only be infused

    Drug: Norepinephrine infusion

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of post-spinal hypotension

    Time frame: Baseline (T0), just after spinal anaesthesia (T1) then every 2.5 minutes until delivery of the fetus

Secondary outcomes

  1. Incidence of bradycardia

    Defined as heart rate \< 55 bpm

    Time frame: Baseline (T0), just after spinal anaesthesia (T1) then every 2.5 minutes until delivery of the fetus

  2. Reactive hypertension

    Defined as SBP \> 120% from the baseline reading

    Time frame: Baseline (T0), just after spinal anaesthesia (T1) then every 2.5 minutes until delivery of the fetus

  3. Systolic blood pressure

    Time frame: Baseline (T0), just after spinal anaesthesia (T1) then every 2.5 minutes until delivery of the fetus

  4. Heart rate

    Time frame: Baseline (T0), just after spinal anaesthesia (T1) then every 2.5 minutes until delivery of the fetus

  5. Rescue vasopressor consumption

    Cumulative intraoperative boluses of ephedrine and norepinephrine doses

    Time frame: Just after spinal anaesthesia until delivery of the fetus

  6. Neonatal outcomes Apgar Score

    The Apgar score comprises five components: 1- color, 2- heart rate, 3- reflexes, 4- muscle tone, and 5- respiration, each of which is given a score of 0, 1, or 2

    Time frame: Within 5 minutes of baby delivery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

Of 61 non-industry phase 4 interventional studies under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 6 months is below that.

Counting every sponsor, half of 62 studies reached it within 12 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Jan 30, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
Faculty of Medicine, Cairo University, Cairo is now Recruiting
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    Faculty of Medicine, Cairo University, Cairo is now Recruiting
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07379710
Lead sponsor
Cairo University
Responsible party
Mohamed Youssef (Assistant Professor, Cairo University) — Principal investigator
First posted
Jan 30, 2026
Start date
Jun 1, 2026
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Mohamed AMY AMY Ollaek, Assistant Professor
Contact
ollaekm@kasralainy.edu.eg
+20100 659 5598
Islam Reda, Lecturer
Contact
islam.reda@kasralainy.edu.eg
+201003315095
Mohamed A Ollaek, MD
principal investigator · Faculty of Medicine, Cairo University, Cairo

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ephedrine · Norepinephrine

Start the discussion